Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy
Year: 2018
Type: article
Abstract: OBJECTIVE A precision approach to type 2 diabetes therapy would aim to target treatment according to patient characteristics. We examined if measures of insulin resistance and secretion were associated with glycemic response to dipeptidyl peptidase 4 (DPP-4) inhibitor therapy. RESEARCH DESIGN AND METHODS We evaluated whether markers of insulin resistance and insulin secretion were associated with 6-month glycemic response in a prospective study of noninsulin-treated participants starting DPP-4 inhibitor therapy (Predicting Response to Incretin Based Agents [PRIBA] study; n = 254), with replication for routinely available markers in U.K. electronic health care records (Clinical Practice Research Datalink [CPRD]; n = 23,001). In CPRD, we evaluated associations between baseline markers and 3-year durability of response. To test the specificity of findings, we repeated analyses for glucagon-like peptide 1 (GLP-1) receptor agonists (PRIBA, n = 339; CPRD, n = 4,464). RESULTS In PRIBA, markers of higher insulin resistance (higher fasting C-peptide [P = 0.03], HOMA2 insulin resistance [P = 0.01], and triglycerides [P < 0.01]) were associated with reduced 6-month HbA1c response to DPP-4 inhibitors. In CPRD, higher triglycerides and BMI were associated with reduced HbA1c response (both P < 0.01). A subgroup defined by obesity (BMI ≥30 kg/m2) and high triglycerides (≥2.3 mmol/L) had reduced 6-month response in both data sets (PRIBA HbA1c reduction 5.3 [95% CI 1.8, 8.6] mmol/mol [0.5%] [obese and high triglycerides] vs. 11.3 [8.4, 14.1] mmol/mol [1.0%] [nonobese and normal triglycerides]; P = 0.01). In CPRD, the obese, high- triglycerides subgroup also had less durable response (hazard ratio 1.28 [1.16, 1.41]; P < 0.001). There was no association between markers of insulin resistance and response to GLP-1 receptor agonists. CONCLUSIONS Markers of higher insulin resistance are consistently associated with reduced glycemic response to DPP-4 inhibitors. This finding provides a starting point for the application of a precision diabetes approach to DPP-4 inhibitor therapy.
Source: Diabetes Care
DOI: 10.2337/dc17-1827
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: type 2 diabetes, DPP-4 inhibitors, insulin resistance, insulin secretion, glycemic response, HbA1c, triglycerides, obesity, body mass index, C-peptide, HOMA2, GLP-1 receptor agonists, precision medicine, treatment response prediction, durability of response, electronic health records, Clinical Practice Research Datalink
Open Access status: green
Awards: MICA: MRC APBI STratification and Extreme Response Mechanism IN Diabetes - MASTERMIND, MRC APBI STratification and Extreme Response Mechanism IN Diabetes - MASTERMIND, NIHR Senior Investigator Award, New insights from Neonatal Diabetes., Urinary C-peptide creatinine ratio and glycaemic response to incretin based treatments in type 2 diabetes, NIHR Senior Investigator Award, G5856124918, G5943380856, NIHR Senior Investigator Award, NIHR Senior Investigator Award, Stratified medicine in Type 2 diabetes: Insights from the study of drug response., Integrating clinical features and biomarkers to improve diabetes classification and treatment in young adults
OpenAlex ID: W2783977038
